S&P Futures
4,085.25 +5.25 (+0.13%) Dow Futures
33,055.00 +11.00 (+0.03%) Nasdaq Futures
13,108.00 +26.00 (+0.20%) Russell 2000 Futures
1,781.80 +1.70 (+0.10%) Crude Oil
74.25 -0.12 (-0.16%) Gold
1,997.30 -0.40 (-0.02%)
TME Pharma NV (0N6A.SG)
Chart Events
Performance Outlook
| Previous Close | 0.9450 |
| Open | 0.9800 |
| Bid | 0.9700 x N/A |
| Ask | 1.0400 x N/A |
| Day's Range | 0.9600 - 0.9800 |
| 52 Week Range | 0.8900 - 16.9000 |
| Volume | |
| Avg. Volume | 86 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for 0N6A.SG
Related Research
- Business Wire
TME Pharma Announces Temporary Suspension of Liquidity Contract With Invest Securities
BERLIN, March 29, 2023--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today that the liquidity agreement entered into with Invest Securities dated September 12, 2016 (Liquidity Contract), has been temporarily suspended as of March 28, 2023, as the company’s shares were traded below the authorization granted by the shareholders at the an
- Business Wire
TME Pharma Announces 83% of Glioblastoma Patients Still Alive After 12 Months on Study (Median) in GLORIA Expansion Arm Evaluating NOX-A12 in Combination With Radiotherapy and Bevacizumab
BERLIN, March 27, 2023--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today a clinical update on survival of newly diagnosed glioblastoma patients in the GLORIA expansion arm evaluating NOX-A12, TME Pharma’s CXCL12 inhibitor, in combination with standard of care radiotherapy and anti-VEGF, bevacizumab.
- Business Wire
TME Pharma CEO Message
BERLIN, February 24, 2023--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), released today a message from Aram Mangasarian, CEO of TME Pharma, to its shareholders with the following key highlights:
